How do migrating birds know where they're going?
Every year, billions of birds migrate in and out of the United States. And across the world, birds fly thousands of miles to reach their seasonal destinations. Some birds, like the Arctic tern (Sterna paradisaea), even rack up enough miles over their lifetime to fly to the moon and back.
But when birds embark on these epic journeys, how do they know where they're going?
Birds have an arsenal of senses they use to orient themselves — some we're familiar with, and some are still beyond human comprehension.
"We know that birds use a variety of cues to keep their migratory direction," Miriam Liedvogel, director of the Institute of Avian Research in Germany, told Live Science in an email.
Sign up for our newsletter
Sign up for our weekly Life's Little Mysteries newsletter to get the latest mysteries before they appear online.
Sight and smell are two basic cues that birds use to find their way. If birds have already migrated once, they'll likely remember familiar landmarks, such as rivers and mountain ranges. Birds that migrate over water, on the other hand, have fewer landmarks to guide them. In these circumstances, they might rely more on their sense of smell; one study found that when researchers blocked the nasal passageways of seabirds called Scopoli's shearwaters (Calonectris diomedea), they could still fly over land but became disoriented when flying over water.
Birds also can use the sun and stars as guides. To do this, birds that fly during the day use a "sun compass," which combines birds' view of where the sun is in the sky with their internal perception of what time of day it is based on their circadian rhythm. By integrating these two inputs, birds can determine the direction they're heading, like a living sundial. Research shows that disrupting a bird's circadian rhythm with artificial light prevents them from navigating accurately, showing the importance of the sun compass.
However, most birds actually migrate at night, meaning the position of the sun is of little use to them. In this case, birds rely on the position and rotation of the stars to find their way. They use this star compass by learning the position of the stars around the celestial pole, which is roughly marked by Polaris (the North Star) — the same star humans have used to navigate for millennia.
Related: Why don't all birds fly?
But what if the sky is cloudy, and birds can't see the sun, stars or any landmarks? That's when birds' more fantastic senses come into play. Birds can find their way even with no sun or stars, partly thanks to a sense called magnetoreception. This sense allows birds to perceive Earth's magnetic fields, which are generated by the rippling molten metals in our planet's core. This feat may sound like science fiction, but research shows that messing with magnetic fields has a big effect on birds; for example, one study found that altering the magnetic fields around pigeons disrupted their homing abilities.
While it's clear that birds are capable of magnetoreception, exactly how they do it is less certain. Peter Hore, a professor of chemistry at the University of Oxford, said birds must utilize some sort of chemical reaction whose outcome depends on the strength and direction of Earth's magnetic field. There are a couple of candidate theories for how this reaction happens, but Hore's bet is on a molecule called cryptochrome, which is present in birds' retinas.
Researchers have confirmed in the lab that isolated cryptochrome responds to magnetic fields and that this reaction requires blue light, which has also been shown to be necessary for bird magnetoreception. Still, researchers aren't exactly sure how cryptochrome is sensitive enough to pick up on tiny variations in Earth's magnetic field.
"We know so little about the details of how this compass might operate," Hore said. "I mean, we don't even know how many cryptochrome molecules there are in the birds' retinas."
Some research also points to a magnetoreception mechanism inside birds' beaks. Studies have found receptors that interact with magnetite, an iron-based mineral, in the upper portion of birds' beaks. These receptors connect to the brain via important nerve pathways, suggesting they could be another technique birds use to gauge the intensity of the magnetic field.
On top of magnetoreception, birds can gain information about their direction by detecting polarized light — a type of light in which the waves oscillate in a specific, aligned plane. Sunlight becomes polarized in predictable ways when light scatters through Earth's atmosphere. Using special cells in their retinas, birds can sense these patterns, which give them information about where the sun is in the sky, even when it's overcast.
Just as we rely on our vision during the day but may use our hands to guide ourselves around a dimly lit room at night, birds employ different senses at different times.
"Birds likely integrate their compass cues to navigate — and we are pretty sure that different cues are of varying importance during their journey," Liedvogel said. Hore pointed this out as well; magnetoreception, for example, is less useful during thunderstorms or periods of high solar activity, both of which can disrupt Earth's magnetic fields, he said.
RELATED MYSTERIES
—Are birds reptiles?
—Why do hummingbirds 'hum'?
—Why are there so many pigeons?
Ultimately, all of these strategies are underpinned by birds' genetic drive to migrate. Birds inherit the propensity to migrate from their parents, Liedvogel explained, and the distance and direction in which they fly are primarily based on genetics. Researchers like Liedvogel are still investigating exactly which genes are responsible and how they work.
Both scientists said understanding these systems will be essential to the future of bird conservation. Relocating or rewilding bird species has become a major focus of wildlife conservation efforts, but so far, outcomes have been mixed; one analysis found that in 45% of studies, the birds left their new location.
"Human efforts to relocate those birds have not been very successful," Hore said. "That's partly because they are such good navigators that if you displace them, they simply fly back."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool
Yahoo
8 hours ago
- Yahoo
Kumail Nanjiani recalls meeting Elon Musk while shooting 'Silicon Valley':' ''He didn't like the show'
Kumail Nanjiani said that Elon Musk was "upset" with the opening scene of Silicon Valley. Nanjiani appeared on an episode of Mike Birbiglia's podcast Working It Out, where he recalled some of the experiences he had with tech giants while on the show. "He didn't like the show," Nanjiani said of Musk. The Eternals actor remembered meeting the Tesla CEO, who said the parties he attended were "much cooler" than those depicted on Silicon Valley. The premiere opens with Kid Rock playing at a tech event to a sparse, dead crowd. "It was like, 'Yeah, man. You're one of the richest people in the world. We're, like, losers on the show. Of course your parties are better than my parties. What are you talking about?'" the Big Sick star said. The comedian also met Mark Zuckerberg while doing the show, but made a bad impression. He and his costar Martin Starr had presented at the Breakthrough Awards, which were co-founded by Zuckerberg, in 2016. During the ceremony, the Silicon Valley actors called back to a joke from the season 1 finale about giving hand jobs to an entire conference room of people. They retooled that bit to accommodate the number of scientists at the Breakthrough Awards and bombed. Nanjiani said he doesn't blame the Facebook founder for disliking him after that moment. "He was like, 'What the f--- was that?'" Nanjiani said. "And truly in that moment he was right." Check out the full episode of Working It Out with Kumail Nanjiani below. Read the original article on Entertainment Weekly


CNN
11 hours ago
- CNN
On GPS: The Trump administration's war on science
Secretary of Health and Human Services Robert F. Kennedy Jr. announced that he is cutting nearly half a billion dollars in federally funded mRNA vaccine research. Fareed speaks with former Baltimore Health Commissioner Dr. Leana Wen about the promises of mRNA technology for treating infectious diseases and the impact of cuts on America's scientists.